We are developing therapies that have the potential to transform the lives of people with severe genetic and rare diseases and cancer. Our current platform is just the beginning. We are committed to continuing to develop gene therapy technologies and capabilities that have broad potential beyond the core indications.

We are actively seeking collaborators and licensing opportunities in the U.S. and around the world to explore the therapeutic potential of our technologies in new cell types and diseases.

We are actively seeking collaborators, in- and out-licensing opportunities to fully leverage the transformational therapeutic potential of our platforms. Specific areas of interest include:

• Novel and impactful applications of bluebird’s megaTAL gene editing technology
• CAR T / TCR immunotherapy targets with highly tumor-specific expression profiles
• Clinically-relevant CAR T / TCR immunotherapy programs with compelling and comprehensive preclinical POC data
• Novel technologies which may enhance key features of CAR T / TCR immunotherapies
• Clinically-relevant viral vector-based gene therapy programs for severe genetic diseases with compelling and comprehensive preclinical POC data
• Novel technologies which may enhance key features of hematopoietic stem cell-based lentiviral gene therapy

Are you interested in partnering with bluebird? Please contact us at partner@bluebirdbio.com

In December 2016, we entered into a strategic manufacturing agreement with apceth Biopharma for the future European commercial production of our Lenti-D™ product candidate for cerebral adrenoleukodystrophy and ZYNTEGLO™ for transfusion-dependent β-thalassemia.  

Under this multi-year agreement, apceth Biopharma will perform clinical manufacturing, process validation activities and commercial manufacturing for  ZYNTEGLO and Lenti-D drug product to support the treatment of European patients with transfusion-dependent beta thalassemia and cerebral adrenoleukodystrophy, respectively. This agreement follows a successful multi-year manufacturing relationship and provides us with European commercial manufacturing capabilities, including dedicated production suites within apceth Biopharma’s state-of-the-art GMP facility.

bluebird bio and Celgene are collaborating to develop CAR T cell therapies targeting BCMA. The collaboration’s lead oncology program, bb2121, is currently being studied for the treatment of relapsed and refractory multiple myeloma. For bb2121, bluebird and Celgene have joint responsibility for development, manufacturing and commercialization in the United States. Celgene will assume sole responsibility for drug product manufacturing and commercialization outside the United States.bluebird bio and Celgene are also working together on a second clinical-stage anti-BCMA CAR T program, bb21217.

In November 2019, we entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), with bluebird’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy platform. This collaboration will focus on a conditioning approach aimed to deliver reduced toxicity and will initially target diseases that have the potential to be corrected with transplantation of autologous gene-modified blood-forming stem cells. If successful, the new conditioning regimen could allow for more patients to undergo gene therapy.

In August 2018, we entered into a strategic research and development collaboration with Gritstone Oncology to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets for use in our established cell therapy platforms.

Under the agreement, Gritstone Oncology will provide 10 tumor-specific targets across several tumor types and, in certain cases, TCRs directed to our targeted indications and will utilize its proprietary technology platform to enable patient selection for clinical development of such therapies.

In January 2019, we announced we have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Inhibrx’s proprietary single domain antibody (sdAb) platform to multiple cancer targets. The small size of sdAbs may enable the generation of more complex CAR T cell products such as those designed to combine additional functions into a single CAR molecule or recognize multiple tumor antigens simultaneously.

Under the terms of the license agreement, Inhibrx will provide bluebird bio the exclusive worldwide rights to develop, manufacture and commercialize certain cell therapy products containing sdAbs directed to various cancer targets. bluebird bio will be responsible for the clinical development and commercialization of the cancer-targeting CAR-T products.

In June 2016, we entered into a strategic manufacturing agreement with Lonza Houston, Inc., providing for the future commercial production of our providing for the potential future commercial production of our drug products: ZYNTEGLO™ for transfusion-dependent β-thalassemia and Lenti-D™ in cerebral adrenoleukodystrophy.

This agreement follows a successful multi-year clinical manufacturing relationship and provides us with a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility. Under this multi-year agreement, Lonza will complete the suite design, construction and validation along with process validation prior to anticipated commercial launch.

In September 2016, we entered into a strategic research and development collaboration and licensing agreement with Medigene AG for T cell receptor (TCR) immunotherapies against four targets. In this partnership, Medigene will be responsible for the generation and delivery of the TCRs using its TCR isolation and characterization platform. Following the collaborative preclinical development, bluebird bio will assume sole responsibility for the clinical development and commercialization of the TCR product candidates and will receive an exclusive license for the intellectual property covering the resulting TCRs.

In October of 2019, we entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including hemophilia. During the three-year research collaboration, we’ll will focus on identifying a development gene therapy candidate with the ambition of offering people with hemophilia A a lifetime free of factor replacement therapy.

The research collaboration will utilize bluebird bio’s proprietary mRNA-based megaTALTM technology that has the potential to provide a highly specific and efficient way to silence, edit or insert genetic components. Aligned with Novo Nordisk’s haemophilia portfolio, the research collaboration will initially focus on correcting FVIII-clotting factor deficiency, with the potential to explore additional therapeutic targets.

In August 2018, we announced a tactical collaboration with Regeneron to apply our respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer.

Under the agreement, we will each leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies, as well as T-cell receptors directed against tumor-specific proteins and peptides. In addition, we have jointly selected six initial targets and will equally share the costs of research and development up to the point of submitting an IND application. Under this five-year agreement, additional targets may be selected. When an IND is submitted for a potential cell therapy product, Regeneron will have the right to opt-in to a co-development/co-commercialization arrangement for certain collaboration targets.

In December 2017, we entered into a strategic research collaboration and licensing agreement with TC BioPharm to discover and develop gamma delta CAR T cell product candidates for cancer immunotherapy.

Under the terms of the agreement, TC BioPharm is responsible for development of all targets through Phase 1/2, at which point we have the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis.